Costa Rica is no longer content to be a place where devices are made according to someone else's blueprint.
En las salas del Centro de Convenciones de Costa Rica, líderes de la industria de dispositivos médicos se reunieron para trazar el rumbo de un sector que representa casi la mitad de las exportaciones nacionales. El Foro de Ciencias de la Vida 2026 no fue un ejercicio especulativo, sino una declaración colectiva: la inteligencia artificial ya no es una opción futura, sino la condición del presente competitivo. Costa Rica, que durante décadas ha sido el taller de manufactura de gigantes como Boston Scientific y Medtronic, aspira ahora a convertirse en el laboratorio donde se diseña la próxima generación de inteligencia industrial.
- El sector MedTech costarricense, responsable del 48% de las exportaciones nacionales, siente la presión de un mercado global donde la ventaja competitiva se erosiona trimestre a trimestre.
- Las grandes multinacionales instaladas en el país no están esperando: compiten entre sí para integrar IA y automatización antes que sus pares globales, creando una urgencia que permea todo el ecosistema.
- El Foro de Ciencias de la Vida 2026 articuló cinco apuestas concretas —inspección visual con IA, mantenimiento predictivo, gemelos digitales, automatización robótica de procesos e innovación especializada— como hoja de ruta para la transformación.
- La ambición más profunda del sector va más allá de adoptar tecnología ajena: Costa Rica quiere desarrollar su propia propiedad intelectual y dejar de fabricar exclusivamente según diseños externos.
- El ecosistema de talento bilingüe, infraestructura consolidada y capital de inversión posiciona al país como un punto de entrada privilegiado para startups de tecnología industrial que buscan un mercado activamente dispuesto a adoptarlas.
El 4 de junio, el Centro de Convenciones de Costa Rica reunió a los protagonistas de la industria de dispositivos médicos más relevante de América Latina. El Foro de Ciencias de la Vida 2026, organizado por CINDE, tenía una pregunta central en su agenda: ¿qué viene después? La respuesta fue unánime: la inteligencia artificial.
La magnitud del sector explica la urgencia. La tecnología médica representa el 48% del valor total de las exportaciones costarricenses, con operaciones manufactureras de peso de compañías como Boston Scientific y Medtronic. La conversación en el foro no fue teórica; fue sobre cómo transformar líneas de producción reales, cómo hacer más inteligentes las máquinas y cómo mantener la ventaja en un mercado que no perdona la lentitud.
El foro identificó cinco áreas de apuesta: inspección visual mediante IA capaz de detectar defectos con mayor precisión que el ojo humano; mantenimiento predictivo para anticipar fallas antes de que ocurran; gemelos digitales que permiten simular cambios sin interrumpir la producción; automatización robótica de procesos repetitivos; y, quizás la más ambiciosa, el desarrollo de innovación propia —la idea de que Costa Rica no solo ensamble dispositivos diseñados en otro lugar, sino que genere su propio conocimiento y sus propias patentes.
Esta transformación se apoya en ventajas acumuladas durante años: una fuerza laboral bilingüe con formación en ingeniería, un ecosistema de inversión maduro y una infraestructura que ya sabe cómo operar a escala multinacional. Para las startups de tecnología industrial, ese contexto representa una oportunidad concreta: un mercado de compradores sofisticados que buscan activamente lo que ellas construyen.
El Foro de Ciencias de la Vida 2026 fue, en el fondo, una declaración de intenciones: Costa Rica ya no quiere ser solo el lugar donde se fabrican los dispositivos de otros. La pregunta que queda abierta no es si el país adoptará la IA, sino si la ejecución —startups, grandes empresas y capital— estará a la altura de la ambición.
On June 4th, the Costa Rica Convention Center filled with the people who run Latin America's most consequential medical device industry. They had gathered for the Life Sciences Forum 2026, an annual convening organized by CINDE that has become the region's premier gathering for the life sciences sector. The agenda was straightforward: figure out what comes next. And what comes next, they agreed, is artificial intelligence.
The numbers explain why this matters. Medical technology exports account for nearly half of everything Costa Rica sells abroad—48 percent of the nation's total export value. This isn't a niche industry. Companies like Boston Scientific and Medtronic have built substantial manufacturing operations here, and they are now in the midst of a fundamental shift. The conversation at the forum wasn't theoretical. It was about how to embed AI into production lines, how to make machines smarter, how to compete in a sector where the margin between leading and falling behind narrows every quarter.
The forum outlined five concrete areas where the sector is placing its bets. First: visual inspection powered by artificial intelligence—machines that can spot defects faster and more reliably than human eyes. Second: predictive maintenance, systems that anticipate equipment failure before it happens, cutting downtime and waste. Third: digital twins, virtual replicas of physical manufacturing systems that let companies test changes without disrupting production. Fourth: robotic process automation, the deployment of software robots to handle repetitive tasks. And fifth: a push toward what the organizers called specialized innovation—the idea that Costa Rica shouldn't just manufacture devices designed elsewhere, but should develop its own intellectual property, its own breakthroughs.
What makes this pivot possible is something less tangible but equally real: the country's accumulated advantages. Costa Rica has built a workforce fluent in both Spanish and English, trained in engineering disciplines, accustomed to working for multinational corporations but increasingly interested in building something of their own. The investment ecosystem, supported by CINDE and other institutions, has learned how to back industrial technology companies. The infrastructure exists. The talent exists. The capital exists.
For startups in the industrial technology space, this creates an opening. A young company with expertise in machine vision, or predictive analytics, or automation software can walk into Costa Rica and find not just a market but an entire ecosystem of manufacturers actively looking to adopt exactly what they're building. The major players—Boston Scientific, Medtronic, and others—aren't moving slowly. They're competing to integrate these technologies faster than their global peers. That urgency creates opportunity for the companies that can move fast enough to meet it.
The Life Sciences Forum 2026 was, in essence, a declaration: Costa Rica is no longer content to be a place where medical devices are made according to someone else's blueprint. The country is positioning itself as a hub for the next generation of manufacturing intelligence. Whether that ambition translates into sustained competitive advantage depends on execution—on whether the startups can deliver, whether the established players can integrate these tools without disrupting their current operations, whether the investment capital keeps flowing. But the direction is clear. The conversation has moved from whether to adopt AI and automation to how fast it can be done.
Notable Quotes
Costa Rica offers a unique opportunity for industrial technology startups due to its sophisticated installed base, availability of bilingual engineering talent, and investment ecosystem supported by CINDE.— Forum organizers and CINDE
The Hearth Conversation Another angle on the story
Why does Costa Rica matter for medical device manufacturing in the first place? It seems like an unlikely place for this kind of industry.
It's not luck. The country invested heavily in education and infrastructure decades ago, and it positioned itself as a stable, English-speaking alternative to manufacturing in the United States. Once Boston Scientific and Medtronic set up operations, others followed. Now you have the supply chains, the expertise, the regulatory knowledge all in one place.
And the AI shift—is that something Costa Rica is driving, or is it just following what the big companies want?
Both. The big companies are definitely pulling the sector toward automation because they need to stay competitive globally. But Costa Rica's advantage is that it has the engineering talent and the investment ecosystem to actually build the tools those companies need. That's where startups come in.
So a startup building predictive maintenance software could actually find customers here?
Not just find them—find them actively looking to buy. The manufacturers aren't dabbling in this. They're racing to integrate it. That creates real urgency on the customer side, which is exactly what startups need.
What happens to the workers in the factories if all this automation takes hold?
That's the question nobody at the forum explicitly addressed. The sector is growing, so there's probably room for retraining and transition. But it's real. Automation means fewer hands on the line, which is efficient but also disruptive for people whose livelihoods depend on those jobs.
Is Costa Rica positioned to lead this, or just to participate?
That depends on whether they can move from manufacturing to innovation. The five pillars they outlined—visual inspection, predictive maintenance, digital twins, RPA, and specialized innovation—that last one is the key. If Costa Rica can generate its own intellectual property, not just implement other people's ideas, then it leads. If it just adopts, it participates.